🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Taiwan / NCT07537166
Enrolling by invitation Not applicable

0.01% and 0.025% Atropine Eye Drops Combined Auricular Acupoint Stimulation on Myopia Control and Corneal Endothelium Change

NCT07537166 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2026-04-11
Last updated
2026-06-04

Condition(s) studied

Acupressure

Investigational drug(s) / intervention(s)

Auricular acupoint stimulation0.01% concentration atropine drops0.025% atropine eye drops →Artificial Tears (AT)

Auricular acupoint stimulation: Auricular Eye Point

0.01% concentration atropine drops: 0.5 mL unit dose, preservative-free

0.025% atropine eye drops: 0.5 mL unit dose, preservative-free

Artificial Tears (AT): 0.5 mL unit dose, preservative-free

Study summary

This randomized, double-blind, placebo-controlled pilot trial evaluates the efficacy and safety of low-dose atropine (0.01%, 0.025%) combined with auricular acupoint stimulation for myopia control in children. While 0.05% atropine is effective, it may pose corneal toxicity risks, highlighting the need for safer alternatives. Auricular acupuncture has shown potential benefits in systematic reviews.

A total of 420 children aged 6-12 will be randomized into six groups receiving different treatments or placebo, with a 12-week follow-up. The auricular Eye Point will be stimulated, and comprehensive visual and ocular assessments will be conducted, including corneal endothelial monitoring.

This study aims to determine the synergistic effect of combined therapy and provide a safer treatment option, laying the foundation for future large-scale trials.

Eligibility

Sex
ALL
Min age
6 Years
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria: * Children aged 6-12 years * Myopia after cycloplegia (spherical equivalent \> -0.5 D) * Astigmatism and anisometropia \< -2.0 D * Intraocular pressure \< 21 mmHg Exclusion Criteria: * Infection * Ulceration * Eyelid disorders * Ear disorders * Amblyopia or strabismus * Use of other pharmacological or invasive treatments for myopia during the study period (spectacles allowed) * Hematologic or other systemic diseases * Non-compliance with study protocol for more than 7 days * History of atropine allergy * Previous or current use of contact lenses or orthokeratology lenses * Previous or current use of bifocal or progressive lenses

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
China Medical University Hospital Taichung North Strict

More China Medical University Hospital trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07537166 on ClinicalTrials.gov ↗ ← All trials in Taiwan